52X.F MAGLE CHEMOSWED HOLDING

Healthcare Biotechnology Frankfurt Exchange
0.0095 EUR
Close of Nov 11, 2026
0.0005 1.88
Market cap
EUR 196K
P/E
-
P/B
0.02x
ROE
-29.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 52X.F undervalued?

Graham number

The Graham number of MAGLE CHEMOSWED HOLDING cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MAGLE CHEMOSWED HOLDING fundamental analysis

No fundamental analysis for MAGLE CHEMOSWED HOLDING yet.

MAGLE CHEMOSWED HOLDING stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MAGLE CHEMOSWED HOLDING

Magle Chemoswed Holding AB (publ) engages in researching, developing, and manufacturing in the areas of medicinal chemistry and pharmaceutical technology in Sweden, Switzerland, rest of Europe, the United States, Brazil, and internationally. It offers degradable starch microsphere and dextran products; and active pharmaceutical ingredients, as well as engages in the research, development, manufacture, market, and sale of diagnostics products to hospitals, clinics, and pharma…

Full company profile